RANI Stock Forecast: Rani Therapeutics Holdings, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$0.58
−10.40% on the day

The median 12-month analyst price target for Rani Therapeutics Holdings, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 63 of 100 as at 18 Nov 2026 — in the upper half.

Market cap
$74.8M
Ticker Nerd rank
63/ 100
Median analyst target
$6.00
Analysts covering
5
Revenue$1.7M
Operating income−$8.8M
Net income−$8.4M
Free cash flow−$9.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+10.6%
1M
−10.7%
YTD
−57.0%
1Y
−66.8%
From 52W high
−66.8%
From 52W low
+12.5%
$0.52
$1.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Rani Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
63/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Accruals
74
Revisions
71
Issuance
58
Volatility
57
Value
30
Momentum
29
Quality
19

Growth (89): Sales and profits are climbing, and climbing faster than before.

Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RANI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RANI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26RANIHigh $11.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$5.00
Low
$6.00
Median
$11.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Oct 2026Chardan CapitalMaintainsBuy$6.00
21 Aug 2026HC Wainwright & Co.ReiteratesBuy$11
18 Aug 2026Chardan CapitalInitiatesBuy$6.00
20 May 2026Canaccord GenuityMaintainsBuy$5.00
1 Apr 2026Canaccord GenuityMaintainsBuy—
27 Mar 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
21 Oct 2025HC Wainwright & Co.AssumesBuy$11
20 Oct 2025Maxim GroupMaintainsBuy—
16 May 2025OppenheimerMaintainsOutperform—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—
26 Feb 2025Canaccord GenuityMaintainsBuy—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
19 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.MaintainsBuy—
2 Aug 2024OppenheimerInitiatesOutperform—
25 June 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024Maxim GroupInitiatesBuy—
13 June 2024Rodman & RenshawInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RANI.

Market Radar

This page is one stock. Monday covers all of them.

RANI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RANI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Rani Therapeutics Holdings, Inc. returned −66.8% against +9.2% for the S&P 500, dividends included.

RANI vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26RANIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RANI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
10.8×

Cheaper than 12% of US stocks

Price / book
2.1×

Cheaper than 43% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
0.0%

Higher than 29% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−233.6%

Higher than 6% of US stocks

Return on assets
−69.7%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rani Therapeutics Holdings, Inc. has a market value of $74.8M and an enterprise value of $40.1M.

  • Revenue in the twelve months to 30 June 2026: $4.9M.

  • Net income over the same four quarters: −$33.4M, a −685.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.27.

  • Free cash flow in the twelve months to 30 June 2026: −$20.3M.

  • Shares outstanding: 112.5M.

  • Rani Therapeutics Holdings, Inc. employs 69 people — $71K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Nov 2026

Data provided by Twelve Data

Peers

RANI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RANIRani Therapeutics Holdings, Inc.$74.8M63
HURATuHURA Biosciences, Inc.$90.1M24
EQEquillium, Inc.$90.6M52
ANIXAnixa Biosciences, Inc.$90.9M61
ZURAZura Bio Ltd.$91.6M15
PMVPPMV Pharmaceuticals, Inc.$92.1M59
VANIVivani Medical, Inc.$94.7M44

Take a look at RANI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Rani Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RANI

What is the RANI stock price forecast for 2026-2027?

The median 12-month analyst price target for Rani Therapeutics Holdings, Inc. is $6, with estimates ranging from $5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RANI stock a buy right now?

Of the 5 analysts covering Rani Therapeutics Holdings, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rani Therapeutics Holdings, Inc. 63 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RANI?

As at 18 Nov 2026, Rani Therapeutics Holdings, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will RANI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $6, and Ticker Nerd's factor model ranks Rani Therapeutics Holdings, Inc. 63 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RANI stock forecast for 2030?

No analyst covering Rani Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $11 over the next 12 months.

How has RANI stock performed over the past year?

Rani Therapeutics Holdings, Inc. returned -66.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rani Therapeutics Holdings, Inc. do?

Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions.

Company

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions. Rani Therapeutics develops this technology for use across multiple therapeutic areas, including peptides, proteins, antibodies, and oligonucleotides. Its business is centered on advancing drug-delivery solutions that may support patients, physicians, and healthcare systems by making biologic administration more convenient. The company operates in the biotechnology and health care life sciences sectors, where oral delivery platforms are an important area of innovation.

CEO Mr. Talat Imran · 69 employees · United States · https://www.ranitherapeutics.com